<DOC>
	<DOCNO>NCT01547312</DOCNO>
	<brief_summary>This study divide 2 segment , propose qualify fine needle aspiration ( FNA ) platform evaluate hepatic pharmacokinetics low high oral dos Grazoprevir ( MK-5172 ) non-cirrhotic participant chronically infect hepatitis C virus ( HCV ) . The first segment , procedural pilot conduct prior main study , aim ensure optimal execution FNA procedure . During procedural pilot , core needle biopsy ( CNB ) perform participant part standard care , study drug administer , procedure FNA conduct . The second segment , main study , design evaluate feasibility measure Grazoprevir FNA . During main study , drug administer , additional procedure conduct .</brief_summary>
	<brief_title>Evaluation Hepatic Pharmacokinetics Grazoprevir ( MK-5172 ) Participants With Chronic Hepatitis C ( MK-5172-022 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Has chronic compensate HCV infection . No contraindication CNB FNA procedure . Pilot study : All comer chronic HCV already schedule undergo CNB fibrosis stag . Pilot study : Requires diagnostic liver biopsy monitor progression liver disease . Pilot study : Does cirrhosis . Main study : Males nonpregnant postmenopausal female willing use medically acceptable contraception , 6 month longer study . Main study : Body mass index 18.5 32.0 kg/m^2 . Main study : Can avoid aspirin , anticoagulant , non steroidal inflammatory agent . Main study : Has undergone prior treatment treatment naive chronic HCV infection . Exclusion Criteria Main study : History follow : stroke , chronic seizure , major neurological disorder , gastric bypass surgery bowel resection . No viral response prior interferon base therapy . Prior treatment HCV NS3/4A protease inhibitor . History either clinically significant , uncontrolled endocrine , gastrointestinal , cardiovascular , hematological , immunological , renal , respiratory , genitourinary abnormalities/diseases . History neoplastic myeloproliferative disease . Has follow : cirrhosis , decompensated liver disease , advance liver disease , hepatocellular carcinoma , infection human immunodeficiency virus ( HIV ) , hepatitis B . Evidence high grade bridge fibrosis prior liver biopsy chronic hepatitis cause HCV . History illicit drug use alcohol abuse . Had surgery , donate least one unit blood , participate investigational study within 4 week prior screen visit . History multiple and/or severe allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>